New chemotherapy combination for untreated T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a chemotherapy combination called CAOP (four drugs given together) for patients 65 and older with a type of lymphoma called peripheral T-cell lymphoma who have never received cancer treatment before. The goal is to see if this combination works well and is safe for older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older
- You have been diagnosed with peripheral T-cell lymphoma (one of three specific types) and have never received chemotherapy or immunotherapy for it
- Your blood counts, liver function, and kidney function are healthy enough to receive chemotherapy
- You are able to walk around and care for yourself with minimal help (ECOG score 0–2)
- You do not have serious heart disease, uncontrolled infection, or HIV/hepatitis
- You have not had another cancer diagnosis in the past two years (except certain skin cancers or cancers treated in situ)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a chemotherapy combination (aclarubicin plus three other drugs) in patients 60 and older whose cutaneous T-cell lymphoma (a blood cancer affecting the skin) did not respond to previous treatments. The goal is to see if this new combination works better and is safe.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Hear when a new Peripheral T-Cell Lymphoma (PTCL NOS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.